Ophthalmic Preparations : Miscellaneous
IVISU1 “Visudyne powder for infusion” 15 mg/vial
適應症:因年齡相關性黃斑部退化病變引起之主要典型或潛隱性視網膜下中央凹脈絡膜血管新生，病理性近視(PM)或疑似眼組織漿菌症引起之視網膜下中央凹脈絡膜血管新生。
Usual dose:
Classic subfoveal choroidal neovascularization : 6 mg/m2 IV infusion for 10 minutes; followed by light therapy 5 mins after finishing verteporfin infusion. Light dose is 50 J/cm2 of neovascular lesion at intensity of 600 mW/cm2 over 83 seconds.
Adverse effect:
Common: injection site reaction, photopsia, blurred vision, visual field defect, reduced visual acuity.
Serious: atrial fibrillation, hypertension, peripheral vascular disease, Vasovagal attack, malignant neoplasm of gastrointestinal tract; intraocular hemorrhage; increased liver function test; retinal hemorrhage, subretinal hemorrhage, vitreous hemorrhage
健保給付規範：同ranibizumab
14.9.2.新生血管抑制劑 (Anti-angiogenic agents) : Verteporfin (如Visudyne)及Anti-VEGF 如ranibizumab (Lucentis)、aflibercept (Eylea) (100/1/1、 101/5/1、102/2/1、103/8/1、104/5/1、105/2/1、105/7/1)
(3)多足型脈絡膜血管病變型黃斑部病變(PCV)之用藥：Verteporfin (104/5/1)
Ⅰ.病灶限位於大血管弓內(major vessels archade)。
Ⅱ.每次申請給付1支，每次治療間隔至少3個月，每人每眼給付以3次為上限，申請核准後之有效期限為二年。
Ⅲ.每次申請時需另檢附一個月內有效之ICGA照片、治療紀錄及病歷等資料。
Ⅳ.已產生中央窩下(subfoveal) 結痂者不得申請使用。